| Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib. | |
| | |
MedLine Citation:
|
PMID: 15765299 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The tyrosine kinase inhibitor imatinib has been introduced into the treatment of gastrointestinal stromal tumors (GIST). Here we report our results of prolonged treatment in comparison to a similar group of GIST patients who had died before imatinib became available. METHODS: Fourteen patients with recurrent or metastatic GIST were treated with imatinib. Clinical data and tumor samples of ten patients from the pre-imatinib era were available for comparison. Comparative genomic hybridisation (CGH) was performed on tumors to identify changes that may predict response to treatment. RESULTS: Fourteen patients were treated, mean treatment time 22.3 months (1 non-response, 2 progression after initial response, 2 stable diseases, 8 partial responses, 1 complete response). Adverse side effects were mild in general. Survival was higher in the treated group (41.1 months vs. 34.8 months in the historical group). Eleven treated patients are alive. CGH analysis showed comparable numbers of chromosomal aberations in both groups. CONCLUSION: Prolonged treatment with imatinib is safe and effective in patients with recurrent or metastatic GIST. |
| | |
Authors:
|
C G Schindler; T Armbrust; B Gunawan; C Langer; L Füzesi; G Ramadori |
Related Documents
:
|
15817679 - Early molecular response to posttransplantation imatinib determines outcome in mrd+ phi... 12115389 - Chronic myelogenous leukemia in t cell lymphoid blastic phase achieving durable complet... 14670929 - The prognostic impact of autologous stem cell transplantation in patients with chronic ... 17340589 - Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction ... 23668929 - Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurr... 6940459 - Chronic myeloid leukemia. a possible new variant in a child. 12225639 - Relationship between tumor burden and serum thyroglobulin level in patients with papill... 17667529 - Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-tra... 10962309 - Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past w... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Zeitschrift für Gastroenterologie Volume: 43 ISSN: 0044-2771 ISO Abbreviation: Z Gastroenterol Publication Date: 2005 Mar |
Date Detail:
|
Created Date: 2005-03-14 Completed Date: 2005-05-09 Revised Date: 2009-11-11 |
Medline Journal Info:
|
Nlm Unique ID: 0033370 Medline TA: Z Gastroenterol Country: Germany |
Other Details:
|
Languages: eng Pagination: 267-73 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology and Endocrinology, Georg August University, Göttingen, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / administration & dosage, adverse effects, therapeutic use* Chromosome Aberrations DNA, Neoplasm / genetics Female Gastrointestinal Stromal Tumors / diagnosis, drug therapy*, genetics, mortality Humans Immunohistochemistry Liver Neoplasms / radiography, secondary Male Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local Nucleic Acid Hybridization Piperazines / administration & dosage, adverse effects, therapeutic use* Prognosis Protein Kinase Inhibitors / administration & dosage, adverse effects, therapeutic use* Pyrimidines / administration & dosage, adverse effects, therapeutic use* Retrospective Studies Risk Factors Safety Time Factors Tomography, X-Ray Computed |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/DNA, Neoplasm; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 152459-95-5/imatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surgical strategies for the prevention of gastrointestinal tumours
Next Document: Symptoms in patients with adenocarcinoma of the esophagus